From today, May 31st, to June 1st, the European Biomanufacturing Summit is taking place in Berlin, Germany. This event brings together key department representatives from global companies such as Bayer, AstraZeneca, Boehringer Ingelheim, Ipsen, Amgen, Abbie, and others to discuss and collaborate on biosimilars and biopharmaceuticals with a focus on Europe, following a previous event held in the United States.The Global Sales Team at Prestige Biologics is sensing a vibrant market atmosphere in Europe that is becoming more active than before. With the end of the COVID-19 pandemic, many global pharmaceutical companies are now engaging in discussions about stable supply chains for the development, production, and distribution of new stages of biopharmaceuticals. Both the U.S. and European biopharmaceutical markets are actively preparing for a new future.Various global companies are concerned about rapid production expansion of pharmaceuticals and actively exploring potential CDMO partners who can flexibly respond to these demands. In contrast to 2022, the biopharmaceutical market in 2023 is undergoing significant changes. Instead of previous expansion strategies involving M&A or direct facility expansion, companies are now more meaningfully evaluating collaborations and partnerships with diverse entities.By leveraging customer-centric facilities and technical service capabilities, Prestige Biologics is expanding touchpoints with potential future customers and deepening relationships.(Prestige Biologics Global Sales Division, Berlin)Prestige Biologics has secured a significant track record over the past few years. It has sufficiently demonstrated its production capabilities for monoclonal antibody biosimilars through its pipeline, such as HD201 and HD204, and has simultaneously proven its capabilities in the development and production of novel antibodies. Additionally, Prestige Biologics' Alita Smart BioFactory, a technological model for bioprocessing, is being recognized for its practical application and improvements in productivity and efficiency.The Alita Smart BioFactory technology from Prestige Biologics is an advanced technological model. It facilitates the rapid market launch of customer products. Particularly, it explains the ability to scale up to 2,000 liters and then scale out by connecting 2,000L single-use bioreactors, providing ideal flexibility to meet evolving customer demands. European customers also understand the challenges of responding to diverse demands with fixed stainless-steel bioreactors larger than 10,000 liters. Therefore, the validated production capacity of Prestige Biologics, which rapidly expands production capacity with a focus on 2,000L single-use bioreactors, is gaining more attention. Global companies are expected to show interest in Prestige Biologics' choices and focus, which consider potential future diversification of customer demands as important decisions, not just changes in technology.During the first half of 2023, Prestige Biologics has increased its interactions with potential customers by several times compared to the previous year. Extending these efforts, it is preparing a dedicated booth and participating in the BIO USA event to be held in Boston from June 5th to June 8th.Prestige Biopharma plans to introduce its pipeline held by the group and discover possibilities for deeper collaborations. It also plans to expand touchpoints with global customers and pursue partnerships that foster deeper relationships.With its accumulated process technology development capabilities, experience and technical expertise in improving production efficiency, and the ability to support efficient collaboration with customers, Prestige Biologics aims to be a unique partner that leads customers' major pipelines to commercial production.Prestige Biologics strives to earn trust from customers as an extension of their team, contributing to human life and growing as a pivotal entity.

Prestige Biologics participates in the BioProcess International 2022 to be held from September 27 to 30 in Boston, USA.BioProcess International is a global bioprocessing event covering novel science across all phases of bioprocessing for biologic. Its agenda includes manufacturing strategy, upstream and downstream processing optimization, and quality, providing the opportunity of learning the latest practice and building network.At the event, Prestige Biologics operates its own dedicated booth, featuring the company’s CDEMO service, top-notch facilities and equipment, and proprietary technology ‘ALITA Smart BioFactory’ to attract global biopharmaceuticals and target potential clients.

Prestige Biologics has participated in the BIOPLUS-INTERPHEX KOREA 2022 which was held from August 3 to 5 at COEX, Seoul, Korea.BIOPLUS-INTERPHEX KOREA 2022 is a bio-pharmaceutical exhibition that encompasses biopharmaceutical Value Chain and proposes ways to expand overseas by building global business networks. In this year's event, around 200 companies from 15 countries participated and 350 booths were open.At the booth, Prestige Biologics attracted the eyes of participants and visitors with its distinctive CDEMO service which is a concept to add Engineering to the existing CDMO service, providing customized solutions for biomanufacturing process. In addition, many visitors showed interest in Prestige Biologics' proprietary technologies and facilities, particularly the 'ALITA Smart BioFactoryFM' and 'Single-Use System'.During the event, Prestige Biologics put various efforts to raise profile such as conducting surveys and giving free gifts. The company also discussed collaborations and partnerships with various global biopharmaceutical companies.

In line with the new government’s plan to nurture Korea’s Bio-health industry, Prestige Biologics is devoting itself to expanding business and stepping up as a global CDMO. On July 27, the government announced an industrial innovation plan that includes providing more support for the development of local COVID-19 vaccines and treatments, ways to increase private investment, and the easing of unnecessary regulations. Earlier, Prestige Biologics has announced that it will invest KRW 169.9 billion in vaccine and biologics manufacturing facilities by 2023. With its global scale biomanufacturing facilities that boast a total production capacity of 154,000L, the company is advancing to the global CDMO market. In addition, Prestige Biologics is also reinforcing its vaccine business with Plant 3 (Voyager) which is a manufacturing facility dedicated to vaccines with 88,000L capacity. Prestige Biologics has gained recognition for its state-of-the-art facilities and proprietary technology. The company has acquired four biomanufacturing-related patents this year alone and won the Best CDMO Award in ‘Korea Bioprocessing Excellence Award 2022’ last June. Currently Prestige Biologics is focusing on securing new clients and contracts by participating in international exhibitions and establishing a new division dedicated to business development.

Topic : Biopharmaceutical Manufacturing from Clinical to Commercial Stage by Single Use System- Event : 11th Biologics Manufacturing Korea- Conference : Enhancing Korea's Vein-to-Vein Supply Chain Management with the Right Technology, Governance and Strategies - Presentation Date : June 29, 2022​- Venue : Songdo Convensia, Incheon, Korea

Prestige Biologics (CEO Yang Jae-young), specializing in biopharmaceutical CDMO, has won the Best CDMO Award at the Korea Bioprocessing Excellence Awards 2022, which was held on June 29 at the Songdo Convention Center in Incheon, South Korea.The Korea Bioprocessing Excellence Awards, held by IMPAC, aims to recognize organizations within Korea that have engaged in substantial efforts to innovate, optimize processes, and uphold a high level of efficacy, quality, and safety in biological products manufacturing. With high reputation on its biomanufacturing facilities and technologies, Prestige Biologics has been recognized as the winner of the Best CDMO Award this year for contributing to reducing cost, improving speed, and enhancing quality in bioprocessing.